Shifting drugs from Part B to D could cost patients, Avalere warns

An analysis conducted by Avalere Health LLC found that patients' out-of-pocket costs for cancer treatments were generally higher when covered under Medicare Part D than under Part B. The analysis follows HHS Secretary Alex Azar's proposal earlier this month that some or all drugs covered

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers